Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Saturday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm reaffirmed a “buy” rating and set a $20.00 price target on shares of Bio-Path in a report on Monday, July 8th.

Bio-Path Stock Performance

Shares of NASDAQ BPTH opened at $0.89 on Friday. Bio-Path has a twelve month low of $0.88 and a twelve month high of $21.60. The company has a 50 day moving average of $1.35 and a 200 day moving average of $2.42.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same period in the previous year, the firm posted ($10.60) earnings per share. On average, sell-side analysts forecast that Bio-Path will post -6.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.